๐ Share this article World Health Organization Raises Concern Over Severe Shortage of Weight-Loss Medications Fewer than a tenth of individuals who could benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it publishes its first guidance on the medications. With over a billion people worldwide currently living with obesity, it is urging more widespread and fairer access to this class of drugs. Per forecasts, over two billion will be living with obesity by 2030 if no action is taken. "The latest guidance acknowledges that excess weight is a chronic disease that can be addressed with thorough and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and logistical bottlenecks are significant obstacles to universal availability to the jabs that can assist patients in reducing considerable body mass, notes the agency. Skinny Jab Scarcity Despite the present most optimistic scenario, the supply of GLP-1 therapies would only suffice for around 100 million people โ under 10% of the global need, as stated by the WHO. The guideline urges nations and manufacturers to increase access, through measures such as patent sharing. The intellectual property rights on semaglutide โ the main ingredient of the drug Wegovy โ is scheduled to end in several nations in 2026. The Way Weight-Loss Injections Operate The injections imitate a biological compound to delay gastric emptying, suppress the appetite and increase satiety so individuals reduce food intake. People usually see weight reduction in the initial weeks of beginning the once-weekly jabs. Studies suggests people may put most of the weight back on after a year of discontinuing the drug, as their typical food cravings return. To be carrying excess weight raises your chance for contracting health problems, such as diabetes, heart disease, stroke, and some malignancies. Excess weight affects people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, as per the health agency.
Fewer than a tenth of individuals who could benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it publishes its first guidance on the medications. With over a billion people worldwide currently living with obesity, it is urging more widespread and fairer access to this class of drugs. Per forecasts, over two billion will be living with obesity by 2030 if no action is taken. "The latest guidance acknowledges that excess weight is a chronic disease that can be addressed with thorough and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and logistical bottlenecks are significant obstacles to universal availability to the jabs that can assist patients in reducing considerable body mass, notes the agency. Skinny Jab Scarcity Despite the present most optimistic scenario, the supply of GLP-1 therapies would only suffice for around 100 million people โ under 10% of the global need, as stated by the WHO. The guideline urges nations and manufacturers to increase access, through measures such as patent sharing. The intellectual property rights on semaglutide โ the main ingredient of the drug Wegovy โ is scheduled to end in several nations in 2026. The Way Weight-Loss Injections Operate The injections imitate a biological compound to delay gastric emptying, suppress the appetite and increase satiety so individuals reduce food intake. People usually see weight reduction in the initial weeks of beginning the once-weekly jabs. Studies suggests people may put most of the weight back on after a year of discontinuing the drug, as their typical food cravings return. To be carrying excess weight raises your chance for contracting health problems, such as diabetes, heart disease, stroke, and some malignancies. Excess weight affects people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, as per the health agency.